GENE ONLINE|News &
Opinion
Blog

2022 psychedelics
Special 2022 psychedelics
Shifting From Counterculture to Clinical Applications, The Problems Psychedelics Face Getting to Market
2022-07-22
Special 2022 psychedelics
Refining Psychedelics into Medicine – An Interview with Doug Drysdale, CEO of Cybin
2022-04-19
Interviews 2022 psychedelics
The Renaissance of Psychedelics Research: An Interview with the CEO of MindMed, Rob Barrow
2022-04-12
Special 2022 psychedelics
WSJ Health Forum 2022: Psychedelics Set to Take Center Stage in Mental Wellness
2022-03-24
Special 2022 psychedelics
Low Doses of LSD as a Potential Treatment for Anxiety in the Future?
2022-03-22
Feature 2022 psychedelics
History on Depression Therapy: the Past and the Psychedelic Future
2022-03-21
Special 2022 psychedelics
Cure or Poison? New Ventures Go IPO Continuously As “Psychedelics” Enter the Mental Health Market
2022-03-09
Special 2022 psychedelics
From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses
2022-03-08
LATEST
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023-11-20
READ MORE
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2023 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top